ecancermedicalscience最新文献

{"title":"Acceptance and barriers to cervical cancer screening among mothers in a state-capital city: a descriptive cross-sectional study.","authors":"Afusat O Oduwoye, Elisha O Olabisi, Elizabeth F Ojo, Taiwo O Dosumu, Michael O Owoeye, Adelani Tijani, Deborah T Esan","doi":"10.3332/ecancer.2025.1916","DOIUrl":"10.3332/ecancer.2025.1916","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a reproductive malignancy that may be detected in its pre-invasive stage by regular cytological screening.</p><p><strong>Objective: </strong>This study assessed the acceptance of cervical cancer screening among mothers attending infant welfare clinics in hospitals in Osogbo, Osun State, Nigeria.</p><p><strong>Methods: </strong>A descriptive cross-sectional design was employed, with questionnaires administered to 355 respondents, selected using Fisher's formula. A multistage sampling technique was used to ensure a representative sample. Data were analysed using descriptive and inferential statistical methods. Relationships between variables were tested using chi-square and Fisher's exact tests at a 5% significance level.</p><p><strong>Result: </strong>Approximately half (46.9%) had adequate knowledge of cervical cancer and its screening. More than half (55.7%) had low susceptibility to cervical cancer. About two-thirds (61.6%) were willing to undergo cervical cancer screening while only a quarter (25.9%) had undergone the screening test. Barriers to cervical cancer screening include lack of awareness, fear, perceived immunity, cost, pain and embarrassment while motivators include integration with general health screenings and perceived necessity. Findings suggest there is a statistically significant association between mothers' age, marital status, ethnicity, knowledge of cervical cancer, susceptibility to cervical cancer and cervical cancer screening acceptability.</p><p><strong>Conclusion: </strong>Acceptance of screening was high which was significantly influenced by their degree of knowledge and susceptibility to cervical cancer. However, screening acceptance was not consistent with their low uptake.</p><p><strong>Implications for practice: </strong>There is a need for continuous education and policies to minimise costs and ensure accessibility to the screening test to promote and improve its uptake thus reducing morbidities and mortalities associated with the disease.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1916"},"PeriodicalIF":1.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185862/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinico-radiological outcomes of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders - early results from the SORASTOP study.","authors":"Bharath B Gangadharaiah, Ghazal Tansir, Sameer Rastogi, Simran Kaur, Vikas Garg, Ekta Dhamija, Adarsh Barwad, Shivanand Gamanagatti, Sandeep Bhoriwal, Maroof A Khan","doi":"10.3332/ecancer.2025.1915","DOIUrl":"10.3332/ecancer.2025.1915","url":null,"abstract":"<p><strong>Introduction: </strong>The duration of treatment for desmoid-type fibromatosis (DTF) is undefined. This study aimed to evaluate the efficacy of discontinuing sorafenib in responding patients with extremity DTF. We hereby report the initial findings comprising outcomes of 20 evaluable patients enrolled in this study.</p><p><strong>Methods: </strong>This prospective single-arm phase 2 Simon's 2-stage trial enrolled adults with radiologically non-progressive, pain-free (Edmonton Symptom Assessment Scale (ESAS) score <2) extremity DTF post at least 1 year of sorafenib. Sorafenib was discontinued and patients were monitored by clinical examination, magnetic resonance imaging, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and Addenbrooke's Cognitive Examination. Disease progression was defined as ≥10% increase in size plus ESAS >5 or ≥20% increase in size. The primary endpoint was a 1-year progression-free survival rate (PFR) after discontinuation. An unplanned analysis of the primary objective among 20 evaluable patients is being presented in this study.</p><p><strong>Results: </strong>33 patients had a median age of 29.5 years (range: 23-38) and a female-to-male ratio of 1.2:1. Median duration of sorafenib therapy was 24 months (range: 14.5-33.5), and at a median follow-up of 15 months (range: 9-18), 20 patients were evaluable. Among the 20 evaluable patients, 1-year change in tumour size ranged from a 21% decrease to a 32% increase. Three patients restarted sorafenib because of pain with stable disease (<i>n</i> = 2) and radiological progression (<i>n</i> = 1). 6-month and 1-year PFR was 96.7% and 95%, respectively. Statistically significant quality of life (QoL) improvement was demonstrated in insomnia (<i>p</i> = 0.01), diarrhea (<i>p</i> = 0.02), physical (<i>p</i> < 0.001) and social (<i>p</i> = 0.04) functioning at 12 months while neurocognitive functions remained stable.</p><p><strong>Conclusion: </strong>As per the early results, stopping sorafenib can be potentially considered in responding patients with stable extremity DTF after at least 1 year of treatment. With improvement in QoL and an acceptable rate of disease progression upon stopping sorafenib, this treatment discontinuation strategy could be an important consideration in DTF management. Further analysis of the entire study cohort is warranted to establish optimal treatment duration for extremity DTF.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1915"},"PeriodicalIF":1.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostatic stromal tumour of uncertain malignant potential: surgical treatment in a young patient.","authors":"Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston","doi":"10.3332/ecancer.2025.1913","DOIUrl":"10.3332/ecancer.2025.1913","url":null,"abstract":"<p><p>Prostate stromal tumour of uncertain malignant potential is a term used to describe a specialised proliferation of stromal cells within the prostate, most tend to be benign, but some can present with local invasion or progress to prostatic stromal sarcoma with distant metastasis. Fortunately, they represent less than 1% of prostate cancers and only a few cases have been described in the literature. We report a case of a 39-year-old male patient who was referred to our centre with this recent diagnosis in the context of acute urinary retention. After an interdisciplinary consideration, a radical prostatectomy was decided for treatment.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1913"},"PeriodicalIF":1.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of metastatic dermatofibrosarcoma protuberans of the breast to the lungs with imatinib mesylate: a case report.","authors":"Stephen Kpatsi, Joseph Daniels, Kofi Adesi Kyei, Verna Vanderpuye","doi":"10.3332/ecancer.2025.1912","DOIUrl":"10.3332/ecancer.2025.1912","url":null,"abstract":"<p><p>Dermatofibrosarcoma protuberans (DFSPs) is a low-grade mesenchymal tumour of dermal origin. Although lung metastasis is common, primary breast involvement is a very rare occurrence. The head and neck region, trunk and extremities are the common primary sites even though any site of the body may be potentially involved. Complete surgical resection with negative margins is the standard of care for nonmetastatic cases of DFSP. To the best of our knowledge, there have been no previous reports of metastatic DFSP of the breast to the lungs among male patients in sub-Saharan Africa. This case report presents data on a 32-year-old male with metastatic DFSP of the left breast to the lungs who was successfully treated with 800 mg daily imatinib mesylate therapy and achieved a complete radiological and clinical response after 1 year of palliative therapy.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1912"},"PeriodicalIF":1.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric schwannoma with atypical manifestations in an adult patient: case report and literature review.","authors":"Yanet Isabel Carrasco Rojas, Albert Gabriel Turpo Peqqueña, Natalia Camila Zenteno Tejada, Victoria Elena Quispe Pastor, Juan Augusto Martínez San Martín, Evelyn Maria Chambilla Huellcacure","doi":"10.3332/ecancer.2025.1910","DOIUrl":"10.3332/ecancer.2025.1910","url":null,"abstract":"<p><p>Gastric schwannomas (GS) are rare tumours originating from Schwann cells that affect the gastrointestinal tract, posing a diagnostic challenge due to their nonspecific symptoms. We report the case of a 61-year-old female presented with gastric fullness and occasional episodes of abdominal pain. Computed tomography revealed a solid mass in the lesser curvature of the stomach, initially suspected to be a gastrointestinal stromal tumours. During surgery, an exophytic lesion was identified and confirmed histopathologically and immunohistochemically as a gastric schwannoma. GS should be considered in the differential diagnosis of gastric subepithelial tumours. Its diagnosis relies on immunohistochemistry, and surgical resection ensures effective treatment.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1910"},"PeriodicalIF":1.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creating a sustainable and inexpensive dry animal training model for liver surgery in low- and middle-income countries.","authors":"Jeanine Justiniano, Ally H Mwanga, Daniel W Kitua, Nashivai E Kivuyo, Seif Wibonela, Cameron E Gaskill","doi":"10.3332/ecancer.2025.1911","DOIUrl":"10.3332/ecancer.2025.1911","url":null,"abstract":"<p><strong>Background: </strong>The growing global demand for surgical simulation training is particularly challenging in low- and middle-income countries (LMICs), where access to advanced technology is limited. Despite increasing demand for these services, hepatobiliary surgical training in LMICs is constrained by a need for more training facilities and experts. We, therefore, designed a feasible, cost-effective liver surgery training model using bovine liver. We hypothesise that this sustainable model can significantly enhance surgical training in LMICs.</p><p><strong>Methods: </strong>A bovine liver was procured from a local slaughterhouse, with careful preservation of its vascular structures. The specimen was transported to the Muhimbili University of Health and Allied Sciences' Laboratory and prepared using a back-table technique. Major vessels were connected to a water flow system, simulating near-physiological central venous and arterial pressures. These parameters were adjusted to mimic real-time effects, creating a training environment similar to that of an actual surgical candidate.</p><p><strong>Findings: </strong>A partial hepatectomy was successfully performed using the crush-clamping technique. Hydrodynamic alterations and simulated bleeding were effectively managed through the Pringle maneuver, suture ligation and stick-tying techniques. The procedure was completed in approximately 1 hour, with an estimated blood loss of 700 mL.</p><p><strong>Conclusion: </strong>An inexpensive, ethical and sustainable bovine liver model was designed for surgical training. This simulation can be easily replicated in training facilities across LMICs to enhance surgical education, particularly in hepatobiliary surgery.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1911"},"PeriodicalIF":1.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular characterisation of KRAS mutations in non-small cell lung cancer across all stages.","authors":"Carla Climent, Sandra Soriano, Natalia Lopez, Julia Giner, Mari Carmen Blazquez, Ruben Carrera, Marina Sierra, Pablo Cobo, Monica Fragio, Mireia Busquets, Ona Cano I Cano, Alicia Carrasco, Miguel Ángel Seguí, Laia Vila","doi":"10.3332/ecancer.2025.1914","DOIUrl":"10.3332/ecancer.2025.1914","url":null,"abstract":"<p><strong>Introduction: </strong>Kirsten rat sarcoma virus (KRAS) mutations (KRASms) are detected in approximately 25% of non-small cell lung cancer (NSCLC) patients with adenocarcinoma. Next-generation sequencing (NGS) has enabled the identification of diverse KRASm subtypes with distinct prognoses, co-mutation patterns and clinical characteristics. This study aimed to investigate the clinical and pathological characteristics of KRASm patients across all stages of NSCLC.</p><p><strong>Methods: </strong>We analysed NSCLC patients from 2019 to 2021 using the Illumina Focus 52-gene targeted NGS panel, which detects DNA and RNA alterations. PD-L1 expression was assessed using the SP263 antibody. We examined the clinical and pathological characteristics of KRASm patients, including KRASm subtypes and co-mutations.</p><p><strong>Results: </strong>Of the 123 patients, 62 (50.4%) had KRASm, with a median age of 67 years (range 49-92). Of these, 79% were male, 87.1% had adenocarcinomas and only 8.1% were non-smokers. NGS alone was sufficient for molecular characterisation in 19.4% of cases; in 75.8%, an additional single molecular test was required. KRASm subtypes were distributed as follows: G12C (33.8%), G12V (25.8%), G12D (21%) and Q61H (6.5%). G12V was more prevalent in non-smokers (60%). Co-mutations were detected in 24.2% of patients, with PIK3CA being the most frequent. PD-L1 expression >50% was observed in 19.4% of patients. No significant associations were identified between KRAS subtypes and PD-L1 expression levels or co-mutations.Significant differences in the clinical stage were noted across KRASm subtypes. Early-stage disease accounted for 24.19% of KRASm cases, with G12D observed in 40% of these patients. However, G12C and G12V subtypes were more frequently associated with metastatic disease (<i>p</i> = 0.004). While differences in median overall survival were observed across KRASm subtypes, they were not statistically significant (<i>p</i> = 0.5). The presence of co-mutations and high PD-L1 expression was suggested to be associated with a worse prognosis, without reaching statistical significance (<i>p</i> = 0.4 and <i>p</i> = 0.06, respectively).</p><p><strong>Conclusion: </strong>This study underscores the importance of assessing KRAS status and subtypes in NSCLC, particularly in early-stage disease, due to their association with metastatic risk. This could have relevance in treatment strategies and subsequent monitoring, which could necessarily be closer in higher risk patients. Moreover, while PD-L1 status shows potential as a prognostic factor in KRASm patients, further research is needed to confirm this relationship.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1914"},"PeriodicalIF":1.2,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excellent response to trametinib and low dose chemotherapy in a patient with rare RAF1 mutated sarcoma in a tertiary care center in India.","authors":"Anjali Govind, Sameer Rastogi, Sunil Pasricha, Shamim Ahmed, Aastha Goel","doi":"10.3332/ecancer.2025.1907","DOIUrl":"10.3332/ecancer.2025.1907","url":null,"abstract":"<p><p>With the advent of next-generation sequencing, increasingly we can sub classify the soft tissue sarcomas into various subtypes with distinct prognostic and therapeutic implications. Sarcomas with RAF1 mutations are extremely rare and so far, the treatment strategies are not known. Here, we report a case of a 48-year-old lady who initially presented with right ear swelling, which was excised and was suggestive of dermatofibrosarcoma protuberans with S100 expression. After a disease-free interval of 25 months, the patient relapsed with metastasis in the lung. Repeat biopsy and next-generation sequencing (NGS) were suggestive of PDZRN3/RAF1 fusion mutated sarcoma. On presentation, the patient had an Eastern Cooperative Oncology Group performance status of 4 and had respiratory distress due to lung metastasis. After consensus and decision in the molecular tumour board, the patient was started on low-dose trametinib and doxorubicin. After three cycles of treatment, the patient had a partial response and post six cycles she had a near-complete response. This case exemplifies the value of molecular characterisation of soft tissue sarcoma and adds to the already sparse literature for RAF1 mutated sarcomas.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1907"},"PeriodicalIF":1.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An aggressive, unresected pineoblastoma in an adult woman: the role of exclusive radiotherapy - a case report and literature review.","authors":"Salem Ouaddane Alami, Fatima Zahra Abdelli, Samia Khalfi, Fatima Zahra Farhane, Zineb Alami, Touria Bouhafa","doi":"10.3332/ecancer.2025.1909","DOIUrl":"10.3332/ecancer.2025.1909","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;The pineal gland is a small, endocrine structure located in the posterior cranial fossa, playing a critical role in regulating sleep-wake cycles. Pineal parenchymal tumours (PPTs) are rare, accounting for less than 1% of central nervous system malignancies. These tumours include pineocytomas (benign), intermediate-grade tumours (PPTs) and aggressive pineoblastomas (PBL), which represent the most dangerous subtype. PBL are fast-growing, high-grade tumours often classified as grade IV. This paper presents a rare case of unresected PBL in a young woman, leading to bilateral blindness and the role of exclusive radiotherapy (RT) as a treatment modality.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This case report aims to explore the effectiveness of exclusive RT in treating an unresected PBL in a young patient, emphasising the tumour's aggressiveness and the therapeutic challenges it presents.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Case presentation: &lt;/strong&gt;A 35-year-old woman with no significant medical history presented with progressively worsening headaches and visual acuity loss. Imaging revealed a pineal region tumour, confirmed as PBL through stereotactic biopsy. The patient had bilateral papilledema and developed hydrocephalus due to tumour growth, leading to pressure on surrounding structures. Due to the patient's refusal of chemotherapy (CT), RT was chosen as the sole treatment option.RT was delivered in two phases: a craniospinal dose of 36 Gy and a boost of 18 Gy to the tumour. The patient tolerated the treatment well, with only mild nausea and fatigue. Follow-up imaging at 3 months showed a 38% reduction in tumour size and improvement in hydrocephalus, although the patient remained bilaterally blind. At 24 months post-treatment, the tumour remained stable, suggesting a positive long-term outcome with exclusive RT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;PBL are aggressive tumours with a high potential for leptomeningeal dissemination. Surgery, when feasible, is considered the primary treatment for pediatric cases, but in adults, data are sparse. In this case, the patient's refusal of CT made RT the only viable option. Recent studies suggest that RT alone can improve survival, particularly when combined with craniospinal irradiation and tumour boosts. However, the role of surgery and CT in adult PBL remains debated, with mixed results in the literature regarding their impact on overall survival.While some studies indicate no significant survival benefit from extensive tumour resection, others suggest that total resection can improve prognosis. The case highlights that exclusive RT can be a life-saving treatment for patients who cannot undergo surgery or CT, despite the tumour's aggressive nature. Further research is needed to establish standardised protocols for managing adult PBL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;This case demonstrates the potential of exclusive RT as an effective treatment for PBL in patients who cannot undergo surgery. Des","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1909"},"PeriodicalIF":1.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of treatment plans from high-dose-rate-brachytherapy of prostate cancer in Nigeria: findings from pioneer centre.","authors":"Bidemi I Akinlade, Iyobosa B Uwadiae, Abbas A Abdus-Salam, Atara I Ntekim, Ayorinde M Folasire, Mutiu A Jimoh, Afolabi A Oladeji, Foluke O Sarimiye, Adeniyi A Adenipekun","doi":"10.3332/ecancer.2025.1906","DOIUrl":"10.3332/ecancer.2025.1906","url":null,"abstract":"<p><strong>Introduction: </strong>High dose rate (HDR) brachytherapy is a promising therapeutic approach for localised prostate cancer. Optimised treatment plans have been shown to improve disease control and reduce toxicity on the organs-at-risk (OAR).</p><p><strong>Aim: </strong>To report findings from the treatment plan parameters (TPPs) obtained from two different HDR brachytherapy treatment regimens at the University College Hospital, Ibadan Nigeria.</p><p><strong>Methods: </strong>The treatment plans of 90 patients, who had HDR brachytherapy to the prostate gland between August 2020 and October 2023 were considered. All were treated with Bebig Saginova machine, housing Cobalt-60 source, the first multi-channel unit in the country then. 44% of patients received dose of 18 Gy in 2 fractions (category A), while the remaining received 27 Gy in 2 fractions (category B). Treatment plans were generated on the Sagiplan 2.0 treatment planning system from Eckert & Ziegler, BEBIG and relevant TPP were extracted and analysed using IBM SPSS 27.</p><p><strong>Results: </strong>The mean age(years) of patients in Categories A and B were 65.3 ± 6.59 and 66.5 ± 5.32, respectively; their gleason score and prostate-specific-antigen were (7 ± 1; and 7 ± 1) and (12.83 ± 16.32; and 12 ± 17 ng/mL), respectively. The mean volume (cm³) of prostate volume (PVol.) for both categories were 46 ± 21 and 31 ± 8, respectively. The paired <i>t</i>-test performed on TPP from patients in both categories was statistically significant (<i>p</i> < 0.005), except their age (<i>p</i> < 0.873) and dose homogeneity index (<i>p</i> < 0.639). Also, the regression analysis showed that V₁₀₀ is statistically dependent (<i>p</i> < 0.05) on Total Reference Air Kerma, conformal index, Rectum D₁₀ and PVol. in both categories.</p><p><strong>Conclusion: </strong>Although, some level of optimal dose coverage around the prostate gland was achieved for some of the patients, especially those in Category B, there is still room for improvement to minimise the dose to OAR.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"19 ","pages":"1906"},"PeriodicalIF":1.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}